Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 1/20 | 0.69 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.66 |
| ▸ | RNASEL | Q05823 | 4/20 | 0.65 |
| ▸ | KRAS | P01116 | 2/20 | 0.65 |
| ▸ | NT5E | P21589 | 1/20 | 0.64 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.61 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.61 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.61 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.60 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.60 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1620402 | 1.00 | TGM2 (0.69) | TGM2FUT5RNASELKRASNT5E | |
| SCHEMBL23752167 | 0.99 | TGM2 (0.70) | TGM2FUT5RNASELKRASNT5E | |
| SCHEMBL1622482 | 0.93 | TGM2 (0.69) | TGM2FUT5RNASELKRASNT5E | |
| SCHEMBL1622486 | 0.93 | TGM2 (0.69) | TGM2FUT5RNASELKRASNT5E | |
| SCHEMBL720115 | 0.93 | TGM2 (0.68) | TGM2FUT5RNASELKRASNT5E | |
| SCHEMBL20850065 | 0.93 | TGM2 (0.68) | TGM2FUT5RNASELKRASNT5E | |
| SCHEMBL2033285 | 0.93 | TGM2 (0.68) | TGM2FUT5RNASELKRASNT5E | |
| SCHEMBL23149534 | 0.93 | TGM2 (0.68) | TGM2FUT5RNASELKRASNT5E | |
| SCHEMBL15747230 | 0.93 | TGM2 (0.68) | TGM2FUT5RNASELKRASNT5E | |
| SCHEMBL4308355 | 0.92 | TGM2 (0.70) | TGM2FUT5RNASELKRASNT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1644394-B1 | SYNTHESIS AND COMPOSITIONS OF 2 -TERMINATOR NUCLEOTIDES | ROCHE DIAGNOSTICS GMBH (DE) | 2018-05-09 | — | — | EP | disclosed |
| EP-1641943-B1 | 2'-TERMINATOR NUCLEOTIDE-RELATED METHODS AND SYSTEMS | ROCHE DIAGNOSTICS GMBH (DE) | 2013-03-20 | — | — | EP | disclosed |
| US-8163487-B2 | 2′-terminator nucleotide-related methods and systems | ROCHE MOLECULAR SYSTEMS, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20110201002-A1 | 2'-Terminator Nucleotide-Related Methods and Systems | ROCHE MOLECULAR SYSTEMS, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| US-7947817-B2 | Nucleotide blocked with sugar compound; biosynthesis of nucleic acids | ROCHE MOLECULAR SYSTEMS, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-7928207-B2 | use of 2'-terminator nucleotides to effect chain termination; kits; incubating a template nucleic acid with a nucleotide incorporating biocatalyst, and a 2'-terminator nucleotide | ROCHE MOLECULAR SYSTEMS, INC (US) | 2011-04-19 | — | — | US | disclosed |
| US-7919249-B2 | use of 2'-terminator nucleotides to effect chain termination; kits; incubating a template nucleic acid with a nucleotide incorporating biocatalyst, and a 2'-terminator nucleotide | ROCHE MOLECULAR SYSTEMS, INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-7572581-B2 | 2′-terminator nucleotide-related methods and systems | ROCHE MOLECULAR SYSTEMS, INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-20090142810-A1 | 2'-Terminator Nucleotide-Related Methods and Systems | ROCHE MOLECULAR SYSTEMS, INC. (US) | 2009-06-04 | — | — | US | disclosed |
| US-20070219361-A1 | Synthesis and compositions of nucleic acids comprising 2'-terminator nucleotides | ROCHE MOLECULAR SYSTEMS, INC. (US) | 2007-09-20 | — | — | US | disclosed |
| EP-1641943-A2 | 2'-TERMINATOR NUCLEOTIDE-RELATED METHODS AND SYSTEMS | Roche Diagnostics GmbH (DE) | 2006-04-05 | — | — | EP | disclosed |
| US-20050037398-A1 | 2'-terminator nucleotide-related methods and systems | ROCHE MOLECULAR SYSTEMS, INC. (US) | 2005-02-17 | — | — | US | disclosed |
| US-20050037991-A1 | Synthesis and compositions of 2'-terminator nucleotides | ROCHE MOLECULAR SYSTEMS, INC. (US) | 2005-02-17 | — | — | US | disclosed |
| WO-2005005667-A2 | 2'-TERMINATOR NUCLEOTIDE-RELATED METHODS AND SYSTEMS | ROCHE DIAGNOSTICS GMBH (DE) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050037991-A1 | Synthesis and compositions of 2'-terminator nucleotides | RNGTT, NT5C3B, NSUN2 | TGM2 1647/4885FUT5 179/4885RNASEL 37/4885 |
| US-20070219361-A1 | Synthesis and compositions of nucleic acids comprising 2'-terminator nucleotides | RNGTT, POLRMT, NT5C3B | TGM2 743/4885FUT5 900/4885RNASEL 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.